EP Wealth Advisors LLC Makes New $222,000 Investment in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

EP Wealth Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 1,106 shares of the biopharmaceutical company’s stock, valued at approximately $222,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in ALNY. Belpointe Asset Management LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth $25,000. KB Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $35,000. Archer Investment Corp acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $40,000. 1832 Asset Management L.P. acquired a new stake in shares of Alnylam Pharmaceuticals in the first quarter valued at $88,000. Finally, Northwestern Mutual Wealth Management Co. grew its stake in shares of Alnylam Pharmaceuticals by 59.4% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 373 shares of the biopharmaceutical company’s stock valued at $89,000 after buying an additional 139 shares in the last quarter. Institutional investors and hedge funds own 93.98% of the company’s stock.

Alnylam Pharmaceuticals Stock Performance

Alnylam Pharmaceuticals stock opened at $179.77 on Tuesday. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $178.21 and a fifty-two week high of $242.97. The company has a market capitalization of $22.47 billion, a P/E ratio of -20.88 and a beta of 0.45. The stock has a 50-day simple moving average of $194.05 and a 200-day simple moving average of $195.50.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.21) earnings per share for the quarter, missing the consensus estimate of ($1.72) by ($0.49). The firm had revenue of $318.75 million during the quarter, compared to analysts’ expectations of $331.73 million. Alnylam Pharmaceuticals had a negative net margin of 85.95% and a negative return on equity of 1,287.80%. As a group, analysts forecast that Alnylam Pharmaceuticals, Inc. will post -6.79 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In related news, CMO Pushkal Garg sold 3,461 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $643,226.85. Following the transaction, the chief marketing officer now owns 8,511 shares in the company, valued at approximately $1,581,769.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Yvonne Greenstreet sold 4,057 shares of the business’s stock in a transaction dated Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $753,993.45. Following the transaction, the chief executive officer now owns 35,216 shares in the company, valued at approximately $6,544,893.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Pushkal Garg sold 3,461 shares of the business’s stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $185.85, for a total value of $643,226.85. Following the transaction, the chief marketing officer now owns 8,511 shares in the company, valued at approximately $1,581,769.35. The disclosure for this sale can be found here. Insiders have sold 15,144 shares of company stock worth $2,806,347 in the last quarter. Company insiders own 1.40% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on the company. HC Wainwright reaffirmed a “buy” rating and issued a $405.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Monday. Stifel Nicolaus reaffirmed a “buy” rating and issued a $240.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Thursday, September 14th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $210.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Friday, August 4th. Sanford C. Bernstein lowered their target price on Alnylam Pharmaceuticals from $247.00 to $233.00 in a research note on Wednesday, July 26th. Finally, StockNews.com began coverage on Alnylam Pharmaceuticals in a research note on Thursday, August 17th. They set a “hold” rating for the company. Six equities research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $247.40.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases.